United Kingdom · Report · Written statement
UIN HCWS711
Correction to Written Parliamentary Questions
Introduced
17 April 2023
Last action
17 April 2023 · Written statement
Status
Commons
Sponsors
—
Subjects
Discovery layer
Source updated
17 April 2023
Summary
Between May and June 2022, 13 Parliamentary Questions (PQs) were answered regarding the UK Health Security Agency testing Covid-19 variants for a Pre-Exposure Prophylaxis antibody therapy (tixagevimab and cilgavimab), known by the brand name Evusheld. The...
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
17 April 2023
Written statement
Between May and June 2022, 13 Parliamentary Questions (PQs) were answered regarding the UK Health Security Agency testing Covid-19 variants for a Pre-Exposure Prophylaxis antibody therapy (tixagevimab and cilgavimab), known by the brand name Evusheld. The...
Source: Commons
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-statements/detail/2023-04-17/HCWS711
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenstatements/statements/1610998
- uk · ws-1610998 · source updated 17 April 2023